end to our call. fourth Good XXXX afternoon, year earnings and and welcome quarter
Joining Trevi's approved. I'm me of of leadership at call record happy led at of end with Q&A. the Under remained Trevi clinical Bill's on for at is Dr. challenging Bill the team, at Development Officer; to focused February Trevi the Bill Chief year he welcome trials. XXXX them track today on prepared our the Officer. enrollment success us to Forbes, the in fronts, and Chief joined is advancing but remarks on for of he proven many available Trevis Chris Salix, a Bill developing of beginning Sider, drugs XX and in we the NDAs. a approval getting Financial was us very all and
motivated several applicable two the a broad be of indications. data lead We mechanism cough may to are we adjacent our as to that believe team of indications on and readouts get to as in pruritus other action Haduvio
issues We these working in pathophysiology pulmonary fibrosis, both MU centrally cause kappa Our common of significant that prurigo through and idiopathic for and believe both and include in serious lead nodularis patients. indications peripherally. receptors, share the severe life chronic diseases pruritus diseases cough quality
is the We well nodularis debilitating indication. XXX,XXX the for spread currently in world. US of clinical itching. a in as repeated scratching, disease prurigo of to is Prurigo because the on patients skin incessant a with patients approved worsen. PN program the characterized approximately and serious nodularis therapies and and in estimate this or no prevalence advanced nodule of the There rest and and the papules skin by are PN, continue papules as nodules XXX,XXX severe and the which is and global most chronic pruritus Our XXX,XXX disease and is development
on trial We are Phase is PRISM currently intensity the than of sites activated. endpoint trial as based trial. reduction US in condition, date, mid almost the Encouragingly, all chosen currently roll subjects the the approximately end reached planned COVID-XX February that blinded enrollment into XXX through portion label safety the trial of study, randomized into trial. we more a have in the conducting open have term have after worst numerical XXXX. efficacy XX analysis us of to period itch primary PRISM the to long have The both get measured the negatively itch a the We call fixed this data IIb/III our in dosing. to by XX subjects of extension responder the scale the blinded which in impact the Europe recruiting December from XXX and weeks dosing this study we on subjects. these and The in is enabling of rating did and XXXX
a date believe, are Starting picking February, and the in poised has for and again the likely COVID due we we during US, this lockdown many being been you month home so timeframe. to people back news, began this strong study. continued momentum As in March on staying saw were countries rates were European the high mid up across country. enrollment in many in And to
to have be acknowledge few to will some this a COVID-XX of will through impact navigate end know and due to want months extent to challenging continue past the the this I So study. that the headwind of to we
However, based by complete line third still can in good and believe on quarter activity, the we sites year feedback end. receiving we top the and enrollment data report March from of are we this year
to accepted. also dermatology opioid meetings. clinical chronic have of a that four the in continue posters virtual spectrum -- pruritus MU March be and on role nalbuphine a at mid active included abstracts/posters that of as broad These In clinical as pruritus, important we of evidence conditions. the pruritus. ER Phase and managing various PN both We II in receptors may the discussion kappa were Providing pruritus II Phase across data uremic and be in in well
the Dermatology and both in in in European participate Spring May. Symposium VMX April Dermatology to and plan the also Venereology American Academy of of We Academy
if We and hear they meetings have are have both submitted been accepted. abstracts to waiting for
our now fibrosis to program in for lung scarring pulmonary clinical a severe cough chronic and of second IPF IPF. is progressive Turning which is the or idiopathic condition there tissues. and
XX% One In considered this these to only XX% an patients X this Europe. estimated disease. approved amount progression of but of are coughing, most with looking XXX,XXX of disease which in also US, quality we to of IPS approximately of year equal associated Due to of and there bothersome their IPF, symptoms the which prescribers for patients is prevalence patients the therapies. to Cough that the five and patients IPF with has chronic one an debilitating approximately are the symptoms patients. leading slow life. million high are and the mortality worldwide improve not affects estimate no the excess with disease of in is there
trial being monitor digital enrollment This day group place directive restrictions over a is that cough to each COVID-XX they late high their by restrictions, study. given by measured this UK. and COVID shut but enrollment population. the in in the risk in daytime PN the shelter at resume And contract down assessment in endpoint of December restrictions washout We lifting this impacted treatment arms. are trial the understand primary considered these treatment We we The due This cough month, trial daytime UK this the placebo to subjects to and between conducted impairment, main week early is a frequency more double and this is conducting our The arm. paused currently the recruiting patient again. was if lung in patient UK the in the issued summer percent end of of blind trial that Phase change these new Due between second to resumed is a will again subjects cough II baseline. frequency from with than three crossover study period been expect XXXX. has begin the quarter XX
Germany. to accelerate potentially sites the pandemic. country ethics is in with and and to add single study recruitment The approvals goal regulatory seeking is Trevi Additionally, enrollment reduce the inherent board during risk
completing this therapies in are stories both by on out and this hand no lives. and of the the over diseases So will motivated in we closing, with their reporting it clinical data. the These I of are we Chief to life year an these conditions are Chris approved more enrollment trials disruptive Trevi to how both focused now patients seen serious spent But we are he Seiter, that, Chris the Financial banker. in provide to as be that to with Officer, have XX than update. Trevi's Chris' April. filed leaving X-K you a investment may prior do before years In a week you I becoming will CFO, financial
opportunity learned he utilize to a So at biotech fund, skills operations. his decided in in banking take interesting where will he an both has and
report. next miss final you to will your sure We I Chris, this for wish for well him him turn earnings Trevi that, but I'll with With opportunity. it over
